[First experience of using modified high-dose therapy NHL-BFM-90 in diffuse large B-cell lymphosarcoma with primary skin involvement. A case report].
Primary skin large B-cell lymphosarcomas (PLBCL) present with skin lesions, other organs and systems are not involved. As CHOP courses are not high effective in PLBCL, we were the first to treat a patient with modified block therapy NHL BFM-90. A complete remission was achieved after the first course of polychemotherapy and was consolidated by two courses of treatment. Further follow-up is needed.
Zamiatina
V I
VI
Magomedova
A U
AU
Kravchenko
S K
SK
Giliazitdinova
E A
EA
Iliushkina
E A
EA
Zvonkov
E E
EE
Kaplanskaia
I B
IB
Obukhova
T N
TN
Kliasova
G A
GA
Gorgidze
L A
LA
Churakova
Zh V
ZhV
Kremenetskaia
A M
AM
Vorob'ev
A I
AI
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D007770:L-Lactate Dehydrogenase